Fedovapagon

Unassigned

New Medicines

Nocturia in men with BPH

Information

New molecular entity
Vantia
Vantia

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials

Category

Vasopressin V2 receptor agonist, orally active small molecule, with overnight duration of activity
Nocturia is the need to wake and pass urine during the night, with >1 episode/night considered abnormal, and it can have significant impact on QoL. There are many possible causes, and symptoms may be due to combinations (e.g. BPH plus nocturnal polyuria) [4]. Worldwide prevalence (2 or more episodes / night) is about 12% of the population and incidence about 4%, and it is much more common in the over 60 age group [5].
Nocturia in men with BPH
Oral

Evidence based evaluations